VivoSim Labs, Inc. (VIVS): Cash & Equivalents
$5.02M
As of 2026-03-31
$1.67M
As of 2026-06-30
-31.0%
3-year compound annual growth
-33.1%
5-year compound annual growth
-22.2%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $5.02M | -55.6% | 2026-07-14, Balance as of period end |
| 2025-03-31 | $11.31M | +289.9% | 2026-07-14, Balance as of period end |
| 2024-03-31 | $2.90M | -81.0% | 2025-06-05, Balance as of period end |
| 2023-03-31 | $15.30M | -46.6% | 2024-05-31, Balance as of period end |
| 2022-03-31 | $28.68M | -23.3% | 2023-07-14, Balance as of period end |
| 2021-03-31 | $37.36M | +36.6% | 2022-06-10, Balance as of period end |
| 2020-03-31 | $27.36M | -25.0% | 2021-06-15, Balance as of period end |
| 2019-03-31 | $36.48M | -16.6% | 2020-05-28, Balance as of period end |
| 2018-03-31 | $43.73M | -30.3% | 2019-06-03, Balance as of period end |
| 2017-03-31 | $62.75M | +1.1% | 2018-05-31, Balance as of period end |
| 2016-03-31 | $62.09M | +23.8% | 2018-05-31, Balance as of period end |
| 2015-03-31 | $50.14M | +4.1% | 2017-06-07, Balance as of period end |
| 2014-03-31 | $48.17M | +208.2% | 2016-06-09, Balance as of period end |
| 2013-03-31 | $15.63M | n/a | 2015-06-09, Balance as of period end |
| 2012-12-31 | $14.82M | n/a | 2015-06-09, Balance as of period end |
| 2012-03-31 | $10.35M | n/a | 2015-06-09, Balance as of period end |
| 2011-12-31 | $340.0K | +19.3% | 2014-06-10, Balance as of period end |
| 2010-12-31 | $285.0K | n/a | 2014-06-10, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $5.02M | -55.6% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $10.74M | -2.8% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $2.98M | +75.5% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $24.75M | +18.3% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $7.11M | -17.9% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $17.47M | -66.1% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $16.42M | -66.0% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $94.53M | +680.1% |
| Prokidney Corp. (PROK) | 2025-12-31 | $108.54M | +9.5% |
Compare VIVS, ATYR, AIM, INMB side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗